Drug Profile
Decernotinib
Alternative Names: Adelatinib; VRT-831509; VX-509Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Amides; Aminopyridines; Anti-inflammatories; Antirheumatics; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 01 Jul 2014 Vertex completes a phase IIb trial in Rheumatoid arthritis in USA, Argentina, Bulgaria, Czech Republic, Estonia, Germany, Hungary, Mexico, Poland, Romania, Russia, Serbia, Slovakia and Ukraine (NCT01590459) prior to July 2015
- 01 Feb 2014 Vertex Pharmaceuticals completes a phase II trial in Rheumatoid arthritis in USA, South Africa, the Netherlands, Denmark, Lithuania & Estonia (NCT01754935)
- 21 Oct 2013 Interim safety and efficacy data from a phase IIb trial in Rheumatoid arthritis released by Vertex Pharmaceuticals